Delivery Order SPE2DB22D3301-SPE2DB23FX4UT
Award Date 11/1/22
Potential Completion Date 11/2/22
Potential Value $76K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $2,735.65 and has been awarded as a Firm Fixed Price Delivery Order with an ultimate completion date of December 18, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a Department of Defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, under a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that runs through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, and has a ceiling value of $8,360.81. The contract is a Firm Fixed Price Delivery Order with a completion date of November 3, 2023. This contract award is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion 30s to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, in the amount of $56,634.35. The contract has a firm fixed-price pricing type and an ultimate completion date of November 20, 2024. The contract is a delivery order without any set-aside designation, indicating open competition. It...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distributor. The contract has a ceiling value of $8,239.50 and an ultimate completion date of October 25, 2023. It is a delivery order contract with a firm fixed price pricing type. The contract...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a ceiling value of $1,372.38. The contract is a Firm Fixed Price Delivery Order with a performance period ending on June 27, 2025. It is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp...
- This federal contract award is for the supply of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $8,806.64, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of March 6, 2024. The award is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite...
- This federal contract award is for the supply of RESTASIS 0.05% EYE EMULSION 30S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,299.77 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of January 28, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $43,718.11, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a firm fixed-price delivery order with an ultimate completion date of December 7, 2023. The award is not designated with a set-aside and appears to be made through full and open competition. Amerisourcebergen...
- This federal contract award is for the delivery of RESTASIS 0.05% eye emulsion, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The fixed-price delivery order, valued at $4,356.93, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 23, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery...